Tigerlily Foundation: Cancer Support, Advocacy, and Health Equity for Women
Best for
Women affected by cancer, especially younger women and people navigating breast cancer, metastatic breast cancer, disparities in care, peer support, and patient advocacy.
What They Do
Tigerlily Foundation is a national women’s health and oncology nonprofit that provides education, advocacy, empowerment, and hands-on support before, during, and after cancer. Its current work spans peer navigation, patient education, research and clinical-trial engagement, health-equity advocacy, and practical support, with a particularly strong concentration in breast cancer and the needs of younger women.
How They Can Help
· Peer navigation through the EMPOWERHer program for patients, caregivers, and families.
· Education on cancer, treatment, survivorship, clinical trials, and women’s health.
· Advocacy training through the ANGEL program.
· Programs focused on health access, disparities, and representation in cancer care.
· Support initiatives for younger women and people living with metastatic breast cancer.
· Toolkits, guidebooks, videos, and other educational resources.
Who It’s For
Tigerlily broadly serves women before, during, and after cancer, with substantial programming centered on breast cancer, younger women, metastatic disease, and communities facing disparities in access and care.
Why This Resource Matters
Tigerlily sits at the intersection of direct support and systems change. It does not stop at helping an individual patient navigate cancer; much of its work is also designed to train advocates, elevate patient voices, and confront inequities in cancer care.
How to Get Help
Use the Programs section of Tigerlily’s website to find current support, peer-navigation, education, advocacy, and clinical-trial resources. Because individual programs may have specific age, diagnosis, or eligibility requirements, check the program page that best matches what you need.
Editorial note: Tigerlily is broader than a single diagnosis, but its current program portfolio remains heavily breast-cancer-focused. The published page should say that plainly.
